RMR Wealth Builders Sells 430 Shares of Novo Nordisk A/S (NYSE:NVO)

RMR Wealth Builders lowered its position in shares of Novo Nordisk A/S (NYSE:NVO) by 13.1% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,844 shares of the company’s stock after selling 430 shares during the quarter. RMR Wealth Builders’ holdings in Novo Nordisk A/S were worth $245,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the business. Essex Savings Bank raised its position in shares of Novo Nordisk A/S by 8.0% in the 4th quarter. Essex Savings Bank now owns 9,636 shares of the company’s stock valued at $829,000 after buying an additional 715 shares in the last quarter. Sendero Wealth Management LLC boosted its stake in shares of Novo Nordisk A/S by 35.4% during the fourth quarter. Sendero Wealth Management LLC now owns 46,413 shares of the company’s stock valued at $3,992,000 after purchasing an additional 12,142 shares in the last quarter. Sawyer & Company Inc bought a new stake in shares of Novo Nordisk A/S in the 4th quarter valued at about $4,963,000. Pinnacle Bancorp Inc. boosted its stake in shares of Novo Nordisk A/S by 29.0% in the 4th quarter. Pinnacle Bancorp Inc. now owns 1,496 shares of the company’s stock valued at $129,000 after purchasing an additional 336 shares during the last quarter. Finally, Redhawk Wealth Advisors Inc. raised its stake in Novo Nordisk A/S by 12.7% during the fourth quarter. Redhawk Wealth Advisors Inc. now owns 21,361 shares of the company’s stock worth $1,837,000 after buying an additional 2,406 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have commented on NVO. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. BMO Capital Markets dropped their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research note on Monday, December 23rd. Finally, StockNews.com downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Buy” and an average target price of $140.20.

Novo Nordisk A/S Trading Up 0.4 %

NYSE NVO opened at $83.26 on Friday. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. Novo Nordisk A/S has a 52 week low of $80.05 and a 52 week high of $148.15. The business has a 50 day moving average price of $98.82 and a 200-day moving average price of $117.93. The company has a market cap of $373.61 billion, a price-to-earnings ratio of 26.94, a P/E/G ratio of 0.92 and a beta of 0.45.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.